TIDMCREO

Creo Medical Group PLC

17 October 2019

Creo Medical Group plc

("Creo" or the "Company")

UK Endoscopy Training Course

Live demonstrations and training using Creo's Speedboat and CROMA platform

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that Queen Elizabeth The Queen Mother Hospital in Margate ("QEQM Hospital"), part of the East Kent Hospitals University NHS Foundation Trust ("East Kent Trust"), today hosts its third endoscopy training course. The three-day training course will include live demonstrations and hands-on stations training on Creo's Speedboat device.

The Course convenor is Dr Zacharias Tsiamoulos, Consultant in Gastroenterology and Specialist in GI Endoscopy at the East Kent Trust. Dr Tsiamoulos is a key opinion leader in the field of Gastrointestinal ("GI") therapeutic endoscopy and a leading user of Speedboat for colorectal endoscopic submucosal dissection, an advanced surgical procedure using endoscopy to remove gastrointestinal pre-cancerous lesions that have not entered the muscle layer.

A number of the International and National Faculty participants have already been trained on Speedboat through the Company's Clinical Education Programme. These first adopters, as well as other clinicians from multiple international jurisdictions, including Norio Fukami, Professor of Gastroenterology at the Mayo Clinic, Arizona (US), will be able to share their expertise and experience with the East Kent Trust delegates. The full programme and list of attendees are available through the following link: https://meded.ekhuft.nhs.uk/resources/kent2019

About Speedboat and CROMA

Speedboat is the first in a range of endoscopic minimally invasive surgical devices to be cleared for use with the Company's CROMA Advanced Energy platform, which uniquely combines bipolar radiofrequency energy for precise tissue dissection along with microwave energy for highly controlled coagulation and tissue ablation. A growing number of GI Endoscopists in the UK, South Africa, Mainland Europe and the US have now performed multiple successful treatments using Speedboat, removing lesions in both upper and lower GI cases.

Typically, instead of having to undergo surgery under general anaesthetic, these patients only needed sedation and were treated as day patients. As a result, Speedboat helps to reduce the risks associated with alternative open, laparoscopic and existing endoscopic procedures, reducing the length of stay in hospital for the patient and the cost of treatment by transferring therapy from the operating theatre to the endoscopy room.

Craig Gulliford, Chief Executive Officer of Creo, commented: "We are extremely proud that the third Kent Course is underway and will include demonstrations and lectures on the use of Speedboat. In time we expect this to help expand the list of physicians capable of carrying out procedures using our technology. It is paramount that each clinician is mentored and given the best training so they can deliver consistently accurate procedures for the patients and ensure that surgical endoscopy using Creo's technology is safely adopted worldwide."

 
 Creo Medical Group plc                                                +44 (0)129 160 6005 
 Richard Rees (CFO) 
 
 Cenkos Securities                                                     +44 (0)20 7397 8900 
 Stephen Keys / Cameron MacRitchie 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                           Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com 
 Paul McManus                                                     Mob: +44 (0)7980 541 893 
 Lianne Cawthorne                                                 Mob: +44 (0)7515 909 238

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiofrequency energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar RF for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA Advanced Energy platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes that its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, investors.creomedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRABIBDGGBBBGCL

(END) Dow Jones Newswires

October 17, 2019 02:00 ET (06:00 GMT)

Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Creo Medical Charts.
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Creo Medical Charts.